Condition: Wilson Disease · D-Penicillamine · Effect of D-penicilline on Cutaneous Elastity of Wilson's Patient · Sponsor: Centre Hospitalier Universitaire de Saint Etienne
Wilson's disease is a genetic disorder, resulting from an anomaly present on the ATP7B gene located on chromosome 13, causing a progressive accumulation of copper in various organs such as the liver, nervous system and cornea, leading to various hepatic and neurological disorders and a systemic evolution. Currently, the first-line treatment for this disease is D-Penicillamine, which acts by chelation and promotes copper excretion through the urine. Unfortunately, this treatment also has significant side-effects, particularly on the skin. However, the pathogenesis of elastopathy in patients with Wilson's disease has yet to be fully characterized, and needs to be better understood in order to adapt the therapeutic strategy. A silicon mold will be made on Wilson's disease patients, enabling the skin micro-relief to be shaped, and analyzed by confocal laser in comparison with the skin of healthy volunteers.
This description comes directly from the study's public registry record.
Jean Luc PERROT, PHD · (0)4 77 82 83 33 · j.luc.perrot@chu-st-etienne.fr
Eduardo COUCHONNAL-BEDOYA, MD · (0)4 72 35 70 50
Always discuss trial participation with your own doctor first.
| Hospices Civils de Lyon | Bron, France | Recruiting |
| Hôpital Nord CHU de Saint-Étienne | Saint-Etienne, France | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06945081